Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb062019	Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell FT516 Off-the-Shelf NK Cell Cancer Immunotherapy Cleared for Clinical Investigation by FDA Product Candidate Derived from Clonal Master iPSC Line Engineered with Novel CD16 Fc Receptor Clinical Trial to Evaluate Multi-dose Cycles of FT516 for Treatment of Hematologic Malignancies, including in Read All »	View HTML
Toggle SummaryFeb072019	Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day SAN DIEGO , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All »	View HTML
Toggle SummaryFeb202019	Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley , M.D., M.S., a leading expert in Read All »	View HTML
Toggle SummaryFeb222019	Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML
Toggle SummaryFeb282019	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryMar052019	Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States $201 Million in Cash & Short-term Investments as of December 31, 2018 SAN DIEGO , March 05, 2019 (GLOBE Read All »	View HTML
Toggle SummaryMar182019	Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss , Ph.D. Read All »	View HTML
Toggle SummaryApr012019	Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO, Calif. Read All »	View HTML
Toggle SummaryApr022019	Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted at 2019 AACR Annual Meeting Read All »	View HTML
Toggle SummaryApr182019	Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development SAN DIEGO , April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu , M.D. Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.